Randomized phase IV trial comparing efficacy and tolerability of temsirolimus with and without an elevated starting dose in patients with relapsed, refractory mantle cell lymphoma.

被引：1
|
作者：
Bair, A.
Hess, G.
Boni, J.
Offner, F.
机构：
[1] Pfizer Oncol, San Diego, CA USA
[2] Klinikum Johannes Gutenberg Univ, Med Klin & Poliklin 3, Mainz, Germany
[3] Pfizer Inc, Collegeville, PA USA
[4] Univ Ziekenhuis Gent, Ghent, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps222
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS222
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical Efficacy and Management of Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma
    Coiffier, Bertrand
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (04): : 351 - 359
  • [2] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL)
    Krekeler, G.
    Dreyling, M.
    Hess, G.
    Kalanovic, D.
    ONKOLOGIE, 2011, 34 : 269 - 269
  • [3] Efficacy and tolerability in clinical practice account best opportunity Temsirolimus for relapsed and/or refractory Mantle cell lymphoma
    Pohlmann, Birgit-Kristin
    ONKOLOGIE, 2010, 33 (12): : 722 - 723
  • [4] A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma.
    Ansell, Stephen M.
    Tang, Hui
    Kurtin, Paul
    Koenig, Patricia
    Inwards, David J.
    Shah, Keith
    Witzig, Thomas E.
    BLOOD, 2009, 114 (22) : 664 - 665
  • [5] Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
    Ansell, Stephen M.
    Tang, Hui
    Kurtin, Paul J.
    Koenig, Patricia A.
    Inwards, David J.
    Shah, Keith
    Ziesmer, Steven C.
    Feldman, Andrew L.
    Rao, Radha
    Gupta, Mamta
    Erlichman, Charles
    Witzig, Thomas E.
    LANCET ONCOLOGY, 2011, 12 (04): : 361 - 368
  • [6] TEMSIROLIMUS FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: SUPPORTIVE EFFICACY ANALYSES FROM THE PHASE 3 STUDY
    Hess, G.
    Romaguera, J.
    Herbrecht, R.
    Verhoef, G.
    Crump, M.
    Hanushevsky, O.
    Strahs, A.
    Hewes, B.
    Berkenblit, A.
    Coiffier, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 391 - 392
  • [7] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
    Krekeler, G.
    Neuhof, A.
    Dreyling, M.
    Hess, G.
    Kalanovic, D.
    Oncology Research and Treatment, 2015, 38 : 66 - 67
  • [8] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
    Krekeler, G.
    Neuhof, A.
    Dreyling, M.
    Hess, G.
    Kalanovic, D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S656 - S656
  • [9] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
    Krekeler, G.
    Herzberg, C.
    Dreyling, M.
    Hess, G.
    Kalanovic, D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S850 - S851
  • [10] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
    Krekeler, G.
    Dreyling, M.
    Hess, G.
    Kalanovic, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 144 - 145
12345